Boehringer Ingelheim launches atrial fibrillation registry programme

Boehringer Ingelheim has announced the launch of a new worldwide registry programme that aims to broaden understanding of atrial fibrillation (AF) treatment.

The Gloria-AF Registry scheme aims to enrol up to 56,000 patients across 2,200 sites in 50 countries and will assess therapy regimes available for stroke prevention in non-valvular AF and associated patient outcomes.

It will collect key data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist warfarin, acetylsalicylic acid and novel oral anticoagulants such as Boehringer Ingelheim's Pradaxa.

The aim of this project, which is the largest of its kind, will be to offer greater insight into the long-term use of oral antithrombotic therapies among this patient group in a real-world setting.

Gregory Lip, professor of cardiovascular medicine at the University of Birmingham centre for cardiovascular sciences, said: "Gloria-AF is a truly collaborative effort, which brings together leading experts from a number of therapy areas across the globe to gain insights into the changing landscape of stroke prevention in non-valvular AF."

Earlier this month, Boehringer Ingelheim announced plans to expand its 1 Million 1 Mission stroke awareness campaign in 2012 to highlight the link between AF and stroke.